Stock Markets7 minutes ago (Sep 10, 2021 04:26AM ET)
© Reuters. FILE PHOTO: The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, September 7, 2021. REUTERS/Staff
By Sruthi Shankar
(Reuters) -European stocks inched higher on Friday, lifted by technology and luxury shares, while investors weighed risks from tighter monetary policies after the European Central Bank signalled a slowdown of its pandemic-era bond purchases.
The pan-European index rose 0.2%, but was still on course to end the week 0.7% lower amid persisting worries of a slowing global economic recovery.
News of a call between Chinese leader Xi Jinping and U.S. President Joe Biden offered some relief to battered Asian stocks, particularly tech companies that have come under heightened regulatory scrutiny in Beijing.
Tech stocks in Europe rose 0.8%, while luxury stocks got a boost as France’s LVMH rose 1.7% after HSBC recommended buying the stock.
China-exposed miners were also among the top sectoral gainers, while telecoms fell the most.
European stocks found some comfort after the ECB stressed it wasn’t about to close the money taps despite projecting higher growth and inflation for the euro zone.
“The outcome of the meeting is likely to be supportive in the short term,” Unicredit (MI:) analysts said.
“But even if ECB President Christine Lagarde was cautious in highlighting that the decision was a just a recalibration, a “real” tapering is probably coming next year, provided that economic conditions remain good enough,” they added.
European shares have hovered below their mid-August record highs on the back of strong earnings and recovery prospects, but major money houses are sceptical of further gains, particularly in U.S. stock markets that is home to high-growth companies.
Data earlier showed Britain’s economy unexpectedly slowed to a crawl in July as the Delta variant of COVID-19 spread rapidly.
Among other stocks, Fresenius Medical Care (NYSE:) dropped 4.0% after J.P.Morgan downgraded the stock to “underweight”.
BioNTech rose 3.9% after two executives at the German biotech firm told Der Spiegel that the company is set to request approval across the globe for use of its COVID-19 vaccine in children as young as five.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.